Oncotarget

Research Papers:

FGF21 functions as a sensitive biomarker of APAP-treated patients and mice

Rong Li, Chao Guo, Xinmou Wu, Zhaoquan Huang and Jian Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:44440-44446. https://doi.org/10.18632/oncotarget.17966

Metrics: PDF 1767 views  |   HTML 2296 views  |   ?  


Abstract

Rong Li1,*, Chao Guo2,*, Xinmou Wu4, Zhaoquan Huang1,3 and Jian Chen1

1Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guangxi, Guilin 541004, PR China

2Department of Pharmacy, Guigang City People’s Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang, Guangxi 537100, PR China

3Department of Pathology, Affiliated Hospital of Guilin Medical University, Guangxi, Guilin 541004, PR China

4Department of Pharmacy, Guangxi Medical University, Guangxi, Nanning 530021, PR China

*These authors share senior authorship

Correspondence to:

Jian Chen, email: [email protected]

Zhaoquan Huang, email: [email protected]

Keywords: acetaminophen, liver impairment, biomarker, FGF21

Received: January 25, 2017     Accepted: May 06, 2017     Published: May 18, 2017

ABSTRACT

Acetaminophen (APAP) is a common medication that induces hepatocellular damage in a time- or dose-dependent manner. Fibroblast growth factor 21 (FGF21) exerts a series of biological effects, including cellular repair. Compared to clinical diagnosis parameters, we aimed to evaluate whether FGF21 can serve as a sensitive biomarker for APAP-induced liver impairment. In the present study, we discussed comparable data from APAP-treated patients and parallelly established APAP-exposed mice for investigation. The resulting human serological data showed that APAP-treated patients have a visible reduction of FGF21 expression in undetected liver impairment of clinical diagnosis. In the animal study, APAP-exposed livers exhibited normal metabolic functions and liver functions, as revealed by biochemical test and histopathological examination. Endogenous FGF21 concentrations in APAP-treated mice were decreased in sera and liver cells. Moreover, comparable immunoassay data showed that hepatocellular FGF21 expression was reduced in a time-dependent manner. Taken together, these findings elucidate the involvement of abnormal FGF21 expression in early APAP-induced liver impairment. Interestingly, FGF21 may be a promising biomarker of APAP-exposed livers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17966